[7]Fizazi K ,et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial....
[7]Fizazi K ,et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 ;20(5):686-700. [8]Kyriakopoulos CE...
D., Morgan, R. C., Sanders, K., Anderson, J., Popert, R., Masters, J., Parmar, M. and James, N. D. (2008) Results of the feasibility stage of STAMPEDE: A multiarm, multi-stage Phase II/III trial for patients with high risk prostate cancer. Eur. Urol. Suppl. 7, 233...
[2] Fizazi K, Tran N,Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosedhigh-risk metastatic castration-sensitive prostate cancer (LATITUDE): finaloverall survival analysis of a randomised, double...
//doi.org/10.1016/j.eururo.2019.08.006 [2] Fizazi K, Tran N,Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosedhigh-risk metastatic castration-sensitive prostate cancer (LATITUDE): finaloverall survival analysis of a randomised, double-blind, phase 3 trial[J]...
which was really exciting but a little mind-blowing. What we heard discussed, though, was that STAMPEDE was predominantly de novo metastatic disease, so most of these patients came into the trial not having had treatment for their primary prostate cancer. In that population, there seemed to be...
MPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients wit...
To our knowledge, this is the first qualitative study of HCPs to have focused on second-line treatment sequencing; changes to practice due to the STAMPEDE and CHAARTED trial data; adverse-effects of prostate cancer treatment including muscle wastage, compromising treatment and finally prostate cancer...
It recruits men with either newly diagnosed metastatic (M1), high-risk localised, or node-positive (N+) prostate cancer (PCa). The trial tests the addition of further treatments to androgen deprivation therapy (ADT), including docetaxel, zoledronic acid, celecoxib, abiraterone, enzalutamide, and ...
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial There is a need to improve the outcomes for men with high-risk localised, nodal or metastatic prostate cancer, or with aggressively relapsing disease after... D N.,James,...